Trial
NCT04988308
A Study of Bermekimab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Janssen Research & Development, LLC
Collaborators
—
Condition
Hidradenitis Suppurativa
Intervention
Bermekimab
Why stopped
Study has been prematurely terminated as the Interim Analysis 1 efficacy results met the prespecified futility criteria related to the primary endpoint.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-11-13